| Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ... New England Journal of Medicine 373 (17), 1627-1639, 2015 | 10043 | 2015 |
| Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 | 9165 | 2015 |
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6137 | 2012 |
| Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929, 2017 | 4334 | 2017 |
| Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer L Paz-Ares, A Luft, D Vicente, A Tafreshi, M Gümüş, J Mazières, B Hermes, ... New England Journal of Medicine 379 (21), 2040-2051, 2018 | 3402 | 2018 |
| Lung cancer: current therapies and new targeted treatments FR Hirsch, GV Scagliotti, JL Mulshine, R Kwon, WJ Curran, YL Wu, ... The Lancet 389 (10066), 299-311, 2017 | 3082 | 2017 |
| Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, ... New England Journal of Medicine 378 (22), 2093-2104, 2018 | 3075 | 2018 |
| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 3018 | 2009 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2781 | 2018 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2614 | 2017 |
| Nivolumab plus ipilimumab in advanced non–small-cell lung cancer MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ... New England Journal of Medicine 381 (21), 2020-2031, 2019 | 2482 | 2019 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1757 | 2019 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1547 | 2020 |
| Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled … K Park, EH Tan, K O'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ... The Lancet Oncology 17 (5), 577-589, 2016 | 1317 | 2016 |
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ... The Lancet 389 (10072), 917-929, 2017 | 1254 | 2017 |
| First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open … L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ... The Lancet Oncology 22 (2), 198-211, 2021 | 1144 | 2021 |
| Current challenges in cancer treatment J Zugazagoitia, C Guedes, S Ponce, I Ferrer, S Molina-Pinelo, L Paz-Ares Clinical therapeutics 38 (7), 1551-1566, 2016 | 946 | 2016 |
| Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials … L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ... Journal of clinical oncology 35 (35), 3924-3933, 2017 | 904 | 2017 |
| Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, ... Journal of Clinical Oncology 40 (12), 1301-1311, 2022 | 832 | 2022 |
| First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement J Tabernero, GI Shapiro, PM LoRusso, A Cervantes, GK Schwartz, ... Cancer discovery 3 (4), 406-417, 2013 | 794 | 2013 |
kenneth o'byrneQueensland University of Technology; Princess Alexandra Hospital; Translational Research InstituteEmail verificata su qut.edu.au
